Phathom Pharmaceuticals Inc. (NASDAQ:PHAT) finished Wednesday with an addition of $0.26 to close at $15.39, an upside of 1.72 percent. An average of 324,486 shares of common stock have been traded in the last five days. There was a gain of $0.65 in the past week, and it reached a new high 10 times over the past 12 months. The last 20 days have seen an average of 261,881 shares traded, while the 50-day average volume stands at 295,111.
PHAT stock has increased by 2.87% in the last month. The company shares reached their 1-month lowest point of $12.91 on 07/24/23. With the stock rallying to its 52-week high on 08/09/23, shares of the company touched a low of $5.84 and a high of $16.14 in 52 weeks. It has reached a new high 6 times so far this year and achieved 37.17% or $3.97 in price. In spite of this, the price is down -4.65% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
PHAT stock investors should be aware that Phathom Pharmaceuticals Inc. (PHAT) stock had its last reported insider trading activity 69 days ago on Jun 02. In this transaction, the insider spent $22,368. CFO and CBO, Henderson Molly, disposed of 2,110 shares at a price of $12.87 on May 22. The insider now owns more than $27,165 worth of shares. Prior to that, CFO and CBO Henderson Molly went on to Sale 3,439 shares at $7.27 each on Apr 06. An amount of $25,002 was transacted.
Financial Health
The quick ratio of Phathom Pharmaceuticals Inc. for the three months ended March 30 was 9.70, and the current ratio was 9.70, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at $27.3 million compared to revenue of $172.44 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Phathom Pharmaceuticals Inc.’s return on assets was -107.60%.
Earnings Surprise
For the three-month period that ended March 30, Phathom Pharmaceuticals Inc. had $96.64 million in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$37.81 million in the quarter, while revenues were shrunk -7.56%. The analyst consensus anticipated Phathom Pharmaceuticals Inc.’s latest quarter earnings to come in at -$1.26 per share, but it turned out to be -$0.89, a 29.40% surprise. For the quarter, EBITDA amounted to -$29.43 million. Shareholders own equity worth $43.61 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Phathom Pharmaceuticals Inc. (PHAT) price momentum. RSI 9-day as of the close on 09 August was 63.96%, suggesting the stock is Neutral, with historical volatility in this time frame at 40.13%.
As of today, PHAT’s price is $14.83 +4.47% or $0.65 from its 5-day moving average. PHAT is currently trading +6.08% higher than its 20-day SMA and +130.15% higher than its 100-day SMA. However, the stock’s current price level is +33.25% above the SMA50 and +52.20% above the SMA200.
The stochastic %K and %D were 68.87% and 65.54%, respectively, and the average true range (ATR) was 0.72. With the 14-day stochastic at 70.59% and the average true range at 0.73, the RSI (14) stands at 61.48%. The stock has reached 0.21 on the 9-day MACD Oscillator while the 14-day reading was at 0.48.
Analyst Ratings
H.C. Wainwright launched coverage on Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) in its analyst report released on August 09, 2023. The firm assigned the stock a Buy rating.
